ALLIGATOR BIOSCIENCE AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.925 SEK | +1.09% |
|
-9.14% | +34.25% |
Presenter SpeechGreta Eklund (Executives)[Audio Gap]
Second Quarte...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Alligator Bioscience AB is a Sweden-based biotechnology Company that develops antibody-based drugs for cancer treatment. The Company specializes in the development of tumor-targeted immunotherapies, in particular agonist mono- and bispecific antibodies, and is active in the early stages of drug development, from concept to phase II clinical trials. Alligatorâs pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its technology platform, Neo-X-Prime, with MacroGenics Inc. and drug candidates based on the RUBY bispecific platform with Orion Corporation. Its licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. The Company operates domestically.
Calendar
2024-05-06
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.925
SEK
Average target price
2.3
SEK
Spread / Average Target
+148.65%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +34.25% | 63.95M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- ATORX Stock
- News Alligator Bioscience AB
- Transcript : Alligator Bioscience AB, H1 2023 Earnings Call, Jul 13, 2023
